Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Ipilimumab (Primary) ; Pembrolizumab (Primary)
- Indications Melanosis
- Focus Therapeutic Use
- 15 Jul 2016 Status changed from not yet recruiting to recruiting.
- 22 Jun 2016 Planned initiation date changed from 1 May 2016 to 1 Aug 2016.
- 20 Apr 2016 New trial record